Brazilian high court defines mandatory rules for health plans to cover insulin pumps in 2025
In a pivotal decision impacting thousands of Brazilians living with Type 1 Diabetes Mellitus, the Superior Court of Justice (STJ) has established a definitive framework for when health plans must cover insulin pumps. This unanimous ruling by the 2nd Section of the court, under “Theme 1.316,” now serves as an obligatory reference for tribunals across the nation as of 2025.
The equipment, officially known as a continuous insulin infusion system, is critical for patients to meticulously control blood glucose levels through a constant, precise application of the hormone. This technological advancement significantly enhances patient quality of life and helps prevent severe complications associated with fluctuating glucose levels.
Despite the device not being explicitly listed in the mandatory procedures catalog of the National Supplementary Health Agency (ANS), the STJ emphatically declared that this omission does not automatically preclude health plans from providing coverage. The ruling marks a significant victory for patient advocacy groups and individuals who have long struggled with coverage denials.
Unpacking the supreme court’s landmark decision
The STJ’s decision clarifies a complex legal landscape that has historically favored health plan operators. By ruling that the insulin pump does not fall under the exceptions outlined in Law 9.656/1998, commonly known as the Health Plans Law, the court effectively invalidates contractual clauses that automatically exclude coverage for such essential medical devices.
This judicial directive fundamentally alters the balance, compelling health plans to re-evaluate their coverage policies in light of the new mandatory guidelines. The unanimous nature of the ruling further solidifies its authority and minimizes potential avenues for appeal by operators, ensuring consistency in judicial interpretations nationwide.
Coverage expansion beyond the ANS list
A crucial aspect of the STJ’s determination is its alignment with Law 14.454/2022, which expanded the possibilities for covering treatments not explicitly listed by the ANS. This law is now confirmed to apply even to older health insurance contracts, including those signed prior to its enactment, ensuring comprehensive protection for a broader base of beneficiaries.
The principle behind this expansion is to safeguard patients’ rights to necessary medical treatments, even if they are cutting-edge or not yet universally integrated into standard procedure lists. The court’s interpretation reinforces the idea that the ANS rol acts as a minimum guarantee, not an exhaustive limitation, on covered health services.
Individual assessment remains key for approval
While the ruling paves the way for broader coverage, the STJ made it clear that reimbursement for insulin pumps is not automatic. Each request will undergo an individualized judicial analysis, strictly adhering to the criteria established by the Supreme Federal Court (STF) in its judgment of ADI 7265.
This individualized review process is designed to ensure that coverage is granted based on specific medical necessity and compliance with established legal and scientific parameters. It prevents a blanket approval, instead focusing on the unique circumstances of each patient’s case.
The requirement for a thorough review underscores the judiciary’s commitment to balanced decisions, weighing patient needs against the structured framework of health plan regulations. This mechanism aims to maintain fairness while ensuring that only legitimate and evidence-backed claims receive approval.
Patients seeking coverage must therefore be prepared to present a robust case, supported by comprehensive medical documentation. The judicial system is now equipped with clear parameters to guide these evaluations, reducing the previous ambiguity that often led to protracted legal battles.
Essential criteria for successful claims in 2025
For a patient to successfully secure coverage for an insulin pump, several key requirements will be rigorously assessed by the courts. These criteria ensure that the treatment is both medically appropriate and adheres to regulatory standards:
- A clear prescription from the responsible medical professional.
- The demonstrated absence of an adequate therapeutic alternative within the ANS mandatory list of procedures.
- Conclusive scientific evidence attesting to the treatment’s efficacy and safety.
- The device must possess current registration with the National Health Surveillance Agency (Anvisa).
Navigating the pre-judicial process
Before initiating legal action, patients are mandated to have first requested the treatment from their health plan and received a denial deemed “unjustified.” This step is critical as it establishes a record of communication and the plan’s stance, which is then reviewed by the court.
During the analysis of individual cases, judges may consult specialized technical bodies, such as the NatJus. These consultations provide expert medical and scientific evidence to inform judicial decisions, ensuring rulings are grounded in robust health data and current medical consensus.
Future implications for patients and operators
The thesis fixed by the STJ in 2025 will ensure that all judicial actions concerning insulin pump coverage follow these precise parameters. In practical terms, this decision significantly reduces the discretionary obstacles previously employed by health plan operators to deny essential treatment to Type 1 Diabetes patients.
However, it simultaneously preserves the necessity for an individual evaluation of each situation, ensuring that medical necessity and regulatory compliance remain at the forefront of every decision. This new standard offers greater clarity and legal certainty for both patients and health care providers in Brazil.






